Skip to content
Search

Latest Stories

Zealand Pharma and Boehringer Ingelheim's weight-loss drug meets goals in mid-stage trial

Denmark's Zealand Pharma and Boehringer Ingelheim said their experimental obesity treatment achieved up to 14.9% weight loss in a mid-stage trial, lining up a potential contestant in the booming obesity drug market.

In a statement on Wednesday (May 10), the partners said that the Phase II dose-finding trial met its primary endpoint of weight loss after 46 weeks.


Paola Casarosa, head of therapeutic areas at Germany's Boehringer Ingelheim told Reuters the partners are in discussion with regulators about the design of a planned follow-up trial in the third and last phase of testing.

The enormous demand for weight-loss treatments such as Novo Nordisk’s Wegovy, or potentially Eli Lilly's Mounjaro, could support as many as 10 competing products with annual sales reaching up to $100 billion within a decade, mostly in the United States, industry executives and analysts said.

Lilly said about a year ago that Mounjaro was shown to reduce up to 22.5% in weight after 72 weeks of treatment in a much larger late-stage trial.

Before that, a late-stage trial showed that Novo’s Wegovy helped patients obtain a weight loss of about 15-17% over 68 weeks, depending on patient subgroups in the study.

Casarosa said the results could not be directly compared because of differences in trial design and size, reflecting an established view in the academic world.

Zealand shares, however, fell 2.9% at 0937 GMT after jumping as much as 3.3% after the open on concerns among some investors and analysts about the differences and that the drug may command a smaller niche than rivals.

UBS analyst Michael Leuchten noted the initial weight-loss readout was below that of Mounjaro and Phase II trials of another Novo drug candidate called CagriSema, but said a lower price could pave the way into a profitable market segment.

"The obesity market will always come with affordability questions that will split the market into different pockets," said Leuchten.

Gareth Powell, head of healthcare at Zealand shareholder Polar Capital, said participants that were not yet up to the planned maintenance dose could be included in the overall tally, potentially heralding a better weight-loss percentage.

"This is likely the third drug to reach the market for obesity after Lilly and Novo Nordisk," said Powell.

REGULATING APPETITE

The drug, called BI 456906, not only mimics a gut hormone called glucagon-like peptide-1 (GLP-1) which suppresses appetite as do other injectable treatments, but it also imitates another gut hormone called glucagon.

"What we see, and what excites us, is on one hand the weight loss that is consistent with our expectations," said Casarosa.

"But what's more, we see obesity also as a key risk factor in driving many comorbidities in the cardiometabolic space."

Among the drug's targeted effects, the glucagon-based mode of action should help burn more fat when exercising and prevent the harmful build-up of fat in the liver, she said.

Its side effects were "consistent" with what was seen in other injectable GLP-1-based drugs, she said.

An experimental drug by Altimmune with the same dual action as Zealand's helped reduce weight by over 10% in a mid-stage trial, data in March showed, but safety concerns sent its shares tumbling.

Almost 400 participants in the Zealand trial - overweight or obese but not diabetic - were put into five equally large groups by chance, with four getting different doses of the experimental weekly shot and the fifth getting a placebo.

More For You

Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Independent Prescribing: Government aims to complete pathfinder programme evaluation by autumn 2025

Pharmacist prescribers at 210 ‘pathfinder’ sites were allowed to trial prescribing models within integrated primary care services.

Photo credit: gettyimages

Independent prescribing: Pathfinder programme evaluation to be completed by autumn, says Kinnock

Health minister Stephen Kinnock has revealed that the evaluation of the Community Pharmacy Independent Prescribing Pathfinder Programme could be completed by Autumn 2025.

Kinnock was responding to a question from James Naish, Labour MP for Rushcliffe, who asked what steps the minister was taking to ensure continued support for the Pathfinder Programme and independent prescribing to maximise direct prescribing capacity in England.

Keep ReadingShow less
Free morning-after pill at pharmacies to end postcode lottery for patients

Pharmacy technicians will be allowed to supply of drospirenone for contraception under PGD,

gettyimages

Pharmacy contract: Free morning-after pill to be available at pharmacies soon

The UK government has announced that, for the first time ever, the ‘morning-after pill’ or emergency contraceptive pill will be available free of charge at pharmacies on the NHS, ending the postcode lottery women face in accessing the medicine and reducing inequalities.

The Department of Health and Social Care (DHSC) has confirmed a record £3.073 billion funding package for community pharmacies in 2025/26, alongside an additional £215 million to sustain Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
Royal College status: The PDA calls for ‘meaningful and collaborative dialogue’

The profession’s success will depend on collaboration across all sectors, says PDA.

gettyimages

Royal College vote: Less than 7% of GB pharmacists in favour, says PDA

The Pharmacists’ Defence Association (PDA) has criticised the Royal Pharmaceutical Society (RPS) for moving too quickly to a ballot on its proposed transition to a Royal College, arguing that it resulted in low participation from pharmacists in Great Britain.

Announcing the results of the special resolution vote, the RPS said that the outcome was a “clear mandate” in favour of the transformative change.

Keep ReadingShow less